Summary of the Conference Call Records Industry Overview: CRO and CDMO Key Points on CRO Industry - The CRO (Contract Research Organization) industry is facing challenges due to intensified competition and weakened profitability after rapid capacity expansion [1][4] - Orders for CRO companies have decreased due to obstacles in innovative drug financing and changes in pharmaceutical policies, leading to a difficult destocking phase [1][4] - In 2024, the number of drug clinical trials in China is expected to grow by 16%, with Phase III trials increasing by 31%, indicating a push in innovative drug development [1][5] - The proportion of BE (Bioequivalence) trials is close to 50%, while Phase I trials have decreased, suggesting a slowdown in early clinical trials [1][5] - Major CRO companies like Zhaoyan New Drug and Tigermed are still expanding their workforce despite the pressure on profitability, indicating market share growth [1][6] Key Points on CDMO Industry - The CDMO (Contract Development and Manufacturing Organization) industry is significantly driven by large orders, particularly from COVID-19 drug commercialization [2][7] - From 2021 to 2023, major companies like WuXi AppTec, Kelun, and Boteng collectively generated $4.2 billion in revenue from large orders, with profits reaching $1.7 billion [2][7] - The development of the peptide industry is crucial for CDMO companies, with products like Semaglutide driving growth for companies like Nuotai and WuXi AppTec [3][8] - The ADC (Antibody-Drug Conjugate) industry is expected to maintain a compound annual growth rate of over 35% until 2030, reflecting strong demand for outsourcing services [3][8] Future Trends and Opportunities - The CRO industry is undergoing a transformation as companies adjust structures and optimize resource allocation to survive [4][6] - The introduction of new listing standards for unprofitable companies may alleviate financing issues for innovative drug firms, potentially boosting CRO demand [4][6] - The potential of alphablenton, a small molecule drug for chronic disease treatment, is highlighted, with a projected sales figure exceeding $29 billion by 2035 [3][11] - The market for chronic disease treatments is expected to grow significantly, with the global adult obesity population projected to rise from 760 million in 2020 to over 1 billion by 2030 [11][12] Additional Insights - The CRO industry is currently experiencing a downturn, with many small companies facing survival challenges, while leading firms are expanding their market share [4][6] - The complex synthesis routes of products like alphablenton contribute significantly to CDMO value, indicating a shift towards more specialized and high-value offerings [10][11] - The pain management market is projected to exceed $120 billion by 2027, with new drug developments addressing unmet clinical needs [13][14] This summary encapsulates the critical insights from the conference call, focusing on the current state and future outlook of the CRO and CDMO industries, along with emerging opportunities and challenges.

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase of 0.94% but a one-month return of -0.94% [1] - The fund's three-month return is 16.34%, ranking 306 out of 1238 similar funds, while its year-to-date return is 10.10%, ranking 434 out of 1218 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund is managed by two key managers: Ms. Ge Lan, who has been managing it since its inception, and Ms. Zhao Lei, who took over management on July 4, 2025 [2]

Group 1 - The Hong Kong CXO concept stocks experienced a decline, with WuXi Biologics falling over 5% [1] - Kingsoft Biotech dropped more than 3% [1] - Other companies such as Kelaiying (002821), WuXi AppTec (603259), Tigermed (300347), and Zhaoyan New Drug (603127) saw declines of over 2% [1]

公司名稱: 凱萊英醫藥集團（天津）股份有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年7月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 2. 股份分類 ...

Summary of Key Points Core Viewpoint The company, Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd., is undergoing changes in the use of raised funds, including new investment projects, adjustments in investment amounts, and delays in project timelines, to enhance operational efficiency and align with market opportunities. Group 1: Fundraising Overview - The company raised a total of RMB 2,277,875,164.30 from a non-public stock issuance, with a net amount of RMB 2,274,960,656.06 after deducting issuance costs [1][2] - The funds are stored in a dedicated account, regulated by a tripartite agreement among the company, the sponsor, and the bank [2] Group 2: Fund Usage Status - As of June 30, 2025, the company has allocated funds to various projects, including the expansion of its life sciences platform and the construction of a biopharmaceutical R&D base [3][4] - The total investment for the projects is RMB 228,070.62 million, with cumulative investments of RMB 163,909.18 million [4] Group 3: Changes in Fund Usage - The company has proposed to change the use of funds for the "Taixing Project" and redirect remaining funds to new projects, including a chemical macromolecule project and a high-end formulation project [5][6] - The investment amount for the Taixing Project will be reduced by RMB 400 million, with the remaining funds allocated to new projects [6][11] Group 4: New Investment Projects - A new project, the "Chemical Macromolecule Integration Project," will receive RMB 47,367.72 million from the remaining funds, with a total investment of RMB 50,800.00 million [11][12] - The project aims to enhance the company's capacity in the CDMO field and is expected to take 48 months to complete [12][14] Group 5: Financial Performance - The company's total assets as of December 31, 2024, were RMB 3,073,514,644.17, with total liabilities of RMB 2,080,120,300.01 and net assets of RMB 993,394,344.16 [13] - The company reported a revenue of RMB 1,597,172,881.12 and a net profit of RMB 52,163,151.56 for the same period [13] Group 6: Strategic Implications - The changes in fund usage are aligned with the company's long-term strategic planning and are expected to improve operational efficiency and competitiveness [19][20] - The company aims to leverage market trends and enhance its capabilities in innovative drug development, particularly in the chemical macromolecule sector [15][16]

一、董事会会议召开情况 证券代码：002821 证券简称：凯莱英 公告编号：2025-038 凯莱英医药集团（天津）股份有限公司 第四届董事会第六十四次会议决议的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）第四届董事会 第六十四次会议通知于 2025 年 6 月 27 日以电子邮件及书面等形式发送给各位 董事、监事及高级管理人员，会议于 2025 年 7 月 4 日以通讯表决方式召开。公 司应到董事 9 名，实到董事 9 名，公司监事及高级管理人员列席了本次会议。会 议由公司董事长 HAO HONG 先生召集和主持，会议的召集和召开符合《公司法》 及相关法律、法规以及《公司章程》的有关规定。 二、董事会议案审议情况 会议采用通讯方式进行表决，经全体董事审议，通过了如下决议： 1、审议通过了《关于变更部分募集资金用途暨新增募集资金投资项目、调 整部分项目投资金额及延期的议案》 为了进一步提高募集资金使用效率，综合考虑市场情况、行业环境及公司实 际经营需要，公司拟变更募投项目"凯莱英药业（江苏）有限公司生 ...

凯莱英医药集团（天津）股份有限公司 关于变更部分募集资金用途暨新增募集资金投资项目、 调整部分项目投资金额及延期的公告 证券代码：002821 证券简称：凯莱英 公告编号：2025-040 联交易，亦不属于《上市公司重大资产重组管理办法》规定的重大资产重组。现 将有关情况公告如下： 一、募集资金基本情况 （一）募集资金到位情况 经中国证券监督管理委员会证监许可[2020]1912 号文《关于核准凯莱英医 药集团（天津）股份有限公司非公开发行股票的批复》核准，公司于 2020 年 9 月向特定投资者发行人民币普通股（A 股）股票 10,178,731.00 股，每股发行价 为 227.00 元/股，募集资金总额为人民币 2,310,571,937.00 元，扣除承销费用 （不含税）32,696,772.70 元，公司实际收到募集资金人民币 2,277,875,164.30 元，扣除其他发行费用人民币 2,914,508.24 元，实际募集资金净额为人民币 2,274,960,656.06 元。上述资金到账情况业经容诚会计师事务所（特殊普通合 伙）出具容诚验字[2020]100Z0073 号《验资报告》验证。 本 ...

第一创业证券承销保荐有限责任公司 关于凯莱英医药集团（天津）股份有限公司 变更部分募集资金用途暨新增募集资金投资项目、 调整部分项目投资金额及延期事项的核查意见 第一创业证券承销保荐有限责任公司（以下简称"一创投行"或"保荐机构"） 作为凯莱英医药集团（天津）股份有限公司（以下简称"凯莱英"或"公司"）的保 荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交易所股票上市规 则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》、《上市公司募集资金监管规则》等法律和规范性文件的要求，对凯莱英医 药集团（天津）股份有限公司变更部分募集资金用途暨新增募集资金投资项目、 调整部分项目投资金额及延期情况进行了审慎核查。具体情况如下： 一、募集资金基本情况 （一）募集资金到位情况 经中国证券监督管理委员会证监许可[2020]1912 号文《关于核准凯莱英医药 集团（天津）股份有限公司非公开发行股票的批复》核准，公司于 2020 年 9 月 向特定投资者发行人民币普通股（A 股）股票 10,178,731.00 股，每股发行价为 227.00 元/股，募集资金总额为人民币 2,310,57 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-041 凯莱英医药集团（天津）股份有限公司 关于调整部分 H 股募投项目实施地点、 投资金额及延期的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存在 虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日召开第四届董事会第六十四次会议，审议通过了《关于调整部分 H 股募投项目实 施地点、投资金额及延期的议案》。为提高 H 股募集资金使用效率，公司逐步进行项 目布局、稳步推进项目实施，在对相关项目的进展进行动态评估后，拟对部分 H 股募 投项目的投资金额进行调整及延期。该事项尚需提交股东大会审议批准。现将有关事 项公告如下： 一、 调整部分 H 股募投项目实施地点、投资金额及延期基本情况 单位：百万人民币 | 募投项目名称 | 变更前 | 变更前拟使 用募集资金 | 变更后 | 变更后拟使 用募集资金 | 变更前 | | 变更后 完成时 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-039 凯莱英医药集团（天津）股份有限公司 第四届监事会第五十一次会议决议公告 本公司及全体监事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）第四届监事会 第五十一次会议通知于 2025 年 6 月 27 日以电子邮件及书面报告等形式发送给各 位监事，会议于 2025 年 7 月 4 日以通讯方式召开。公司应到监事 3 名，实到监 事 3 名，会议由公司监事会主席智欣欣女士召集，会议的召集和召开符合《公司 法》及相关法律、法规以及《公司章程》的有关规定。 二、 监事会会议审议情况 会议采用通讯方式进行了表决，经全体监事审议并表决，通过了如下决议： 1、审议通过了《关于变更部分募集资金用途暨新增募集资金投资项目、调 整部分项目投资金额及延期的议案》 经审核，监事会认为：公司本次变更部分募集资金用途暨新增募集资金投资 项目，并调整部分募投项目投资金额及项目延期事项是公司出于长远发展战略做 出的慎重决策，有利于提高募集资金使用效率，符合公司及全体 ...